Osimertinib - AstraZeneca

Drug Profile

Osimertinib - AstraZeneca

Alternative Names: AZD-9291; Mereletinib; TAGRISSO

Latest Information Update: 14 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; Dana-Farber Cancer Institute; Eli Lilly; European Organisation for Research and Treatment of Cancer; European Thoracic Oncology Platform; G1 Therapeutics; Incyte Corporation; Kyushu University; Molecular Partners AG; National Cancer Institute (USA); National University Hospital (Singapore); Singapore Clinical Research Institute
  • Class Acrylamides; Aniline compounds; Antineoplastics; Dimethylamines; Indoles; Pyrimidines; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists; Protein tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer
  • Phase II Carcinomatous meningitis
  • Phase I Solid tumours

Most Recent Events

  • 19 Jul 2018 AstraZeneca initiates the phase III LAURA trial for Non Small Cell Lung Cancer (Late-stage disease, Inoperable/Unresectable) in South Korea (PO) (NCT03521154)
  • 12 Jul 2018 Launched for Non-small cell lung cancer (First-line therapy, Late-stage disease) in Canada (PO)
  • 12 Jul 2018 Registered for Non-small cell lung cancer (First-line therapy, Late-stage disease) in Canada (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top